HPGC Renmintongtai Pharmaceutical Corp (600829) - Total Liabilities
Based on the latest financial reports, HPGC Renmintongtai Pharmaceutical Corp (600829) has total liabilities worth CN¥4.29 Billion CNY (≈ $627.74 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check HPGC Renmintongtai Pharmaceutical Corp liquidity resilience to evaluate the company's liquid asset resilience ratio.
HPGC Renmintongtai Pharmaceutical Corp - Total Liabilities Trend (1994–2025)
This chart illustrates how HPGC Renmintongtai Pharmaceutical Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see HPGC Renmintongtai Pharmaceutical Corp asset portfolio.
HPGC Renmintongtai Pharmaceutical Corp Competitors by Total Liabilities
The table below lists competitors of HPGC Renmintongtai Pharmaceutical Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JM AB (publ)
ST:JM
|
Sweden | Skr15.78 Billion |
|
Xianheng International Science & Technology Co Ltd
SHG:605056
|
China | CN¥1.35 Billion |
|
Camden National Corporation
NASDAQ:CAC
|
USA | $6.25 Billion |
|
Pexa Group Ltd
AU:PXA
|
Australia | AU$502.68 Million |
|
TeamViewer AG
F:TMV
|
Germany | €1.62 Billion |
|
CHINA RISUN GROUP HD-10
F:45Y
|
Germany | €46.78 Billion |
|
Power HF Co Ltd
SHG:605100
|
China | CN¥455.28 Million |
|
Summit
TA:SMT
|
Israel | ILA5.48 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down HPGC Renmintongtai Pharmaceutical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See HPGC Renmintongtai Pharmaceutical Corp net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HPGC Renmintongtai Pharmaceutical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HPGC Renmintongtai Pharmaceutical Corp (1994–2025)
The table below shows the annual total liabilities of HPGC Renmintongtai Pharmaceutical Corp from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥4.16 Billion ≈ $608.72 Million |
-2.92% |
| 2024-12-31 | CN¥4.29 Billion ≈ $627.04 Million |
-8.34% |
| 2023-12-31 | CN¥4.68 Billion ≈ $684.11 Million |
+1.72% |
| 2022-12-31 | CN¥4.60 Billion ≈ $672.55 Million |
+1.04% |
| 2021-12-31 | CN¥4.55 Billion ≈ $665.63 Million |
+13.64% |
| 2020-12-31 | CN¥4.00 Billion ≈ $585.75 Million |
+8.18% |
| 2019-12-31 | CN¥3.70 Billion ≈ $541.44 Million |
+30.63% |
| 2018-12-31 | CN¥2.83 Billion ≈ $414.47 Million |
-12.29% |
| 2017-12-31 | CN¥3.23 Billion ≈ $472.56 Million |
+2.12% |
| 2016-12-31 | CN¥3.16 Billion ≈ $462.74 Million |
+12.57% |
| 2015-12-31 | CN¥2.81 Billion ≈ $411.08 Million |
+148.89% |
| 2014-12-31 | CN¥1.13 Billion ≈ $165.17 Million |
-21.82% |
| 2013-12-31 | CN¥1.44 Billion ≈ $211.25 Million |
-17.30% |
| 2012-12-31 | CN¥1.75 Billion ≈ $255.45 Million |
-8.51% |
| 2011-12-31 | CN¥1.91 Billion ≈ $279.23 Million |
+20.60% |
| 2010-12-31 | CN¥1.58 Billion ≈ $231.54 Million |
+32.20% |
| 2009-12-31 | CN¥1.20 Billion ≈ $175.14 Million |
-5.44% |
| 2008-12-31 | CN¥1.27 Billion ≈ $185.22 Million |
-0.69% |
| 2007-12-31 | CN¥1.27 Billion ≈ $186.51 Million |
+10.25% |
| 2006-12-31 | CN¥1.16 Billion ≈ $169.16 Million |
+5.01% |
| 2005-12-31 | CN¥1.10 Billion ≈ $161.09 Million |
+32.94% |
| 2004-12-31 | CN¥828.09 Million ≈ $121.18 Million |
+60.34% |
| 2003-12-31 | CN¥516.46 Million ≈ $75.57 Million |
+27.93% |
| 2002-12-31 | CN¥403.72 Million ≈ $59.08 Million |
-12.16% |
| 2001-12-31 | CN¥459.59 Million ≈ $67.25 Million |
-14.05% |
| 2000-12-31 | CN¥534.74 Million ≈ $78.25 Million |
+85.96% |
| 1999-12-31 | CN¥287.56 Million ≈ $42.08 Million |
+18.95% |
| 1998-12-31 | CN¥241.76 Million ≈ $35.38 Million |
+0.12% |
| 1997-12-31 | CN¥241.46 Million ≈ $35.33 Million |
+3.91% |
| 1996-12-31 | CN¥232.37 Million ≈ $34.00 Million |
+3.57% |
| 1995-12-31 | CN¥224.35 Million ≈ $32.83 Million |
+11.75% |
| 1994-12-31 | CN¥200.76 Million ≈ $29.38 Million |
-- |
About HPGC Renmintongtai Pharmaceutical Corp
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese and Western patent medicines, Chinese herbal medicines and slices, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices, and health products, as well as tonic health, daily necessities, and cosm… Read more